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ABSTRACT
We sought to explore the architecture of trials of calcineurin inhibitors for atopic eczema to
document the extent to which comparisons with active treatments such as topical
corticosteroids (TCS) might have been included or avoided.
We identified all eligible randomized controlled trials (RCTs) using the Global Resource for
EczemA Trials database. Network plots were produced where the nodes represented a
treatment type and the lines between the nodes represented the number of trials or
participants that were involved in the various treatment comparisons.
A total of 174 RCTs for atopic eczema treatments were identified where pimecrolimus,
tacrolimus or topical corticosteroids were compared with another intervention or a
vehicle/emollient. Of 39 trials involving pimecrolimus and of 41 trials involving tacrolimus,
8 (20.5%) and 13 (31.7%) respectively made comparisons with topical corticosteroids, and 25
(64.1%) and 15 (36.6%) respectively were vehicle-controlled studies.
The high rate of comparisons with vehicle controls in RCTs assessing the efficacy of
pimecrolimus or tacrolimus long after efficacy had been established is a matter of concern.
Active comparators (mild TCS for pimecrolimus and moderate to potent TCS for tacrolimus)
are best placed to inform how topical calcineurin inhibitors compare to established clinical
practice.
INTRODUCTION
Atopic eczema, also known as atopic dermatitis or just eczema (Johansson et al., 2004),
affects between 0.9% to 24.6% of children worldwide (Odhiambo et al., 2009) as well as
many adults (Emerson et al., 1998; Yu and Silverberg, 2015). Topical corticosteroids have
been recommended as the first line anti-inflammatory treatment for atopic eczema for over 50
years (Eichenfield et al., 2014; Rattner, 1955). Although their side effect profiles are well
established and are safe when used appropriately, some degree of phobia exists with their use
(Charman et al., 2000). Over the last 10 years, the topical calcineurin inhibitors pimecrolimus
and tacrolimus have been introduced as an alternative form of anti-inflammatory treatment
for atopic eczema and are usually cited as second line treatments in various national
guidelines (American Academy of Dermatology; NICE guidelines, 2014; SIGN Guidelines,
2011). These recommendations are based on evidence from several randomised controlled
trials (RCTs) that have evaluated the efficacy and effectiveness of pimecrolimus and
tacrolimus in the treatment of atopic eczema. However, based on our experience of critically
appraising hundreds of atopic eczema RCTs for various systematic reviews, it was our
impression that relatively few RCTs seem to compare pimecrolimus or tacrolimus directly
with the first line treatment of an appropriate potency topical corticosteroid. In order to
explore this impression in more detail we set out to examine the geometry of randomised
controlled trials for atopic eczema. Inspired by the work of Maruani et al. (Maruani et al.,
2015), we developed a network of all atopic eczema RCTs involving pimecrolimus,
tacrolimus or topical corticosteroids in order to see whether there has been an excess of
vehicle-controlled studies to what might be expected in relation to active comparator studies.
RESULTS
Characteristics of trials
A total of 174 RCTs for atopic eczema treatments were identified whereby pimecrolimus,
tacrolimus or topical corticosteroids were compared with another intervention or a
vehicle/emollient. Of these, 91 (52.3%) stated that the trial was either fully or partly funded
by industry. Table 1 provides further details on the characteristics of these RCTs.
Network of trials
The network plot of all comparisons between treatments from the 174 RCTs is shown in
Figure 1 whereby the size of the node is proportional to the number of trials involving that
intervention and the thickness of the line is proportional to the number of trials comparing the
two interventions. In total, 24 different interventions were assessed within our network.
Eighty five (48.9%) trials involved a comparison with a vehicle or emollient.
A second network plot is given in supplementary material 3 whereby the size of the node is
proportional to the total number of patients who received that intervention across all trials and
the thickness of the line is proportional to the number of patients who were involved in trials
comparing the two interventions.
Several comparisons between interventions were overrepresented in the network. This was
reflected in the co-occurrence analysis which yielded a significant observed C-score of 111.6
with a 95% confidence interval of the simulated C-score under the null hypothesis of 109.6 to
111.3 (p-value=0.003). The upper confidence interval value of the simulated C-score is lower
than the observed C-score meaning that there exists a higher degree of co-occurrence than in
the null hypothesis, the null hypothesis being that the pattern in the choices of treatment
comparisons within the network is random.
Table 2 details the number of comparisons that were made between, pimecrolimus,
tacrolimus, topical corticosteroids and vehicle/emollient. The most clinically relevant
comparators for pimecrolimus are mild and moderate topical corticosteroids (NICE
guidelines, 2014). Pimecrolimus was compared to mild topical corticosteroids in 1 trial and to
moderate topical corticosteroids in 3 trials (2.6% and 7.7% of all trials in the network that
involved pimecrolimus respectively). In contrast, pimecrolimus was compared to a vehicle or
emollient in 25 trials which equates to 64.1% of all trials in the network that involved
pimecrolimus. Five (20%) of the 25 vehicle-controlled trials involved patients with moderate
to severe atopic eczema and 21 (84%) declared that they were funded in full or in part by
industry.
For topical tacrolimus, the most clinically relevant comparators are mild and moderate topical
corticosteroids for 0.03% strength tacrolimus, and moderate and potent topical corticosteroids
for 0.1% strength tacrolimus. Tacrolimus was compared to mild topical corticosteroids in 7
trials (1 involved 0.03% strength tacrolimus, 4 involved 0.1% strength tacrolimus and 2
involved both 0.03% and 0.1%), to moderate topical corticosteroids in 2 trials (both involved
0.1% tacrolimus) and to potent topical corticosteroids in 8 trials (3 involved 0.03% strength
tacrolimus, 4 involved 0.1% strength tacrolimus, and 1 did not state the strength of tacrolimus
used). Fifteen (36.6%) of all 41 trials involving tacrolimus involved a comparison with a
vehicle control. Ten (66.7%) of the 15 vehicle-controlled trials involved patients with
moderate to severe atopic eczema and 10 (66.7%) declared that they were funded in full or in
part by industry.
DISCUSSION
Main findings
Clinicians need good information in order to make the best treatment choices with their
patients in a shared decision-making model. When a new treatment is introduced, clinicians
ideally want to know “is this new treatment better in some way than the treatments that I
already use?” In the case of topical calcineurin inhibitors, such a practical question requires
comparison with existing topical corticosteroids rather than vehicle. Vehicle controlled
studies are of course needed early on in the development of new drugs in order to determine
treatment efficacy and safety. Before a new drug comes onto the market, efficacy and safety
have to be established for licensing purposes, typically through a programme of Phase II
studies and subsequent Phase III studies. Pivotal Phase III studies are typically large vehicle-
controlled studies initially, followed by studies against active comparators later. One can
understand the need for four or maybe five vehicle-controlled trials for topical pimecrolimus
and tacrolimus to establish efficacy and safety in different populations such as children vs.
adults, Hispanics and Blacks compared to White populations and in a few different countries
where treatment pathways might differ.
The network map produced in this study suggests an overkill of vehicle-controlled studies for
topical pimecrolimus (25 trials, 64%) and to a lesser extent, topical tacrolimus (15 trials,
36.6%). The scientific and ethical justification for so many vehicle-controlled studies need to
be questioned, given that scientific equipoise in favour of the active drug is clear after pivotal
studies have been performed. Others have commented that the promulgation of so many
vehicle controlled studies may be construed by some as being unnecessary and a form of
marketing – so called “seeding trials” (Alexander, 2011; Eheberg et al., 2015; Lexchin, 2013;
Rose and Kopp, 2015).
Of the trials involving a comparison between pimecrolimus and vehicle/emollient, tacrolimus
and vehicle/emollient, or topical corticosteroids and vehicle/emollient, 84%, 66.7% and
45.7% respectively declared that they were funded either in full or in part by industry.
Several studies have demonstrated that RCTs sponsored by industry are more likely to
produce results in favour of the product made by that company (Katz et al., 2006; Lexchin et
al., 2003). Following on from this, evidence also shows that industry sponsored trials are
more likely to compare an intervention against an inactive or “straw man” comparator
(Ioannidis and Karassa, 2010; Stamatakis et al., 2013).
The use of network plot for reviewing research priorities
Constructing this network of evidence is a method that can enable researchers and clinicians
to have a complete picture of the evidence for pimecrolimus, tacrolimus and topical
corticosteroids and alert them to treatment comparisons which have not been directly
compared in RCTs. The network has also highlighted areas that currently lack evidence
which will hopefully provide a clearer direction for future research into treatments for atopic
eczema.
Strengths and limitations
Our study does have some limitations. It is possible that we could have missed some
unpublished studies of active comparators that did not show favourable results. We did not
assess the severity of atopic eczema in each individual RCT nor did we assess any other
patient characteristics, for example, age. We also did not write to all of the companies
involved to ask for their reasons why so many vehicle controlled studies were done. It is
possible for example that some countries required new additional vehicle studies to be done
in their own population despite the large volume of clear evidence of efficacy when
compared to vehicle from other countries. It is possible that other new treatments for atopic
eczema have or will illustrate a similar profusion of vehicle controlled studies, but there are
no clear candidates that have been introduced over the last 20 years. One could argue that
topical corticosteroids have also been overly compared against vehicle preparations and that
may be so (46 (36.2%) of 127 involving topical corticosteroids made comparisons with a
vehicle control). Although it should be recognised that 27 different types of topical
corticosteroids have been included in the corresponding nodes in Figure 1, whereas topical
pimecrolimus is just one preparation and topical tacrolimus is just three strengths of the same
preparation. Strengths of the study include the comprehensive inclusion of all published
clinical trials obtained through the GREAT database covering the entire period in which the
two topical calcineurin inhibitors were introduced.
Implications for clinical practice and future research
Clinicians and clinical scientists need to become more involved in designing and participating
in drug trials when new drugs are introduced and should ask how many vehicle controlled
studies have been done and how many more are really needed and for what purpose. Four or
five placebo/vehicle studies might be enough even for a global market. Such an ideal might
be difficult to realise given that clinical investigators are typically paid well for recruiting
patients into such studies. Regulatory bodies might do more to encourage more active
comparisons for Phase III studies, using appropriate existing competitor products at the
correct dose and frequency. Ethical committees should also question how many vehicle
controlled studies have been done before granting permission for more such studies. Most
important of all, the public can be made more aware of the difference between vehicle
controlled and active comparator trials so that they too can make a judgement of when
enough is enough when comparing a new active topical drug against vehicle, especially for
those who have moderate to severe disease.
In addition to suggesting a rebalance towards more active rather than placebo or vehicle-
controlled studies, greater emphasis should be made on the choice of outcomes such as the
core outcome set currently being developed by the Harmonising Outcomes in Eczema
initiative so that studies can be compared directly against each other in systematic review
meta-analyses (Schmitt et al., 2015). In addition to efficacy outcomes, safety outcomes
should also be recorded and reported. For example, the main rationale for bringing topical
calcineurin inhibitors onto the market was concern about possible side effects of topical
corticosteroids such as skin thinning. Yet clinically significant skin thinning has rarely been
reported in such trials. In the largest clinical trial of topical pimecrolimus compared against
mild to moderate topical corticosteroids over a long period, the frequency of clinical skin
thinning was just one out of 1213 children for those using long-term topical corticosteroids
compared with zero out of 1205 in the topical pimecrolimus group i.e. no real difference at all
(Sigurgeirsson et al., 2015). Yet extracting such key information from the trialists took three
attempts by different correspondents, and the key data remains buried in the online
correspondence section of the journal.
There is no doubt that the Pharmaceutical industry is needed and that it has been responsible
for some key innovations in dermatology, including the topical calcineurin inhibitors for
treating atopic eczema at sensitive sites and for preventing flares (Schmitt et al., 2011).
Active rather than passive engagement in drug development from a whole range of
constituencies is what is now needed for new drug developments in dermatology.
MATERIALS AND METHODS
GREAT database
The Global Resource for EczemA Trials (GREAT) database contains records of all RCTs and
systematic reviews of treatments for atopic eczema published since the inception of the
MEDLINE (1966) and EMBASE (1980) (Centre of Evidence Based Dermatology). The
search strategy used to populate the GREAT database is given in Supplementary Material 1.
Searches are also carried out using the Cochrane Library and the Cochrane Skin Group
specialised register of trials from inception, therefore the GREAT database also contains
many records that are not in MEDLINE or EMBASE as a result of handsearching and other
searches done by the Cochrane Skin Group. Further information on the GREAT database can
be found at: http://www.greatdatabase.org.uk.
Selection criteria
The GREAT database was searched to identify all RCTs for atopic eczema up until 4th
December 2014 that incorporated at least one treatment arm involving pimecrolimus,
tacrolimus or topical corticosteroids as an intervention. Any RCTs that only involved intra-
drug comparisons, for example different doses of the same drug, were excluded as we felt it
unlikely that these dose finding studies would have deliberately avoided a lower or standard
dose.
Categorisation of interventions
All doses and regimens of pimecrolimus were grouped together. Tacrolimus was categorised
in strengths 0.03%, 0.1% and 0.3%. Where the strength of tacrolimus was not stated or
participants were allowed to use multiple different strengths within the trial, these were
classified as “any tacrolimus”. Topical corticosteroids were grouped according to potency
(mild, moderate, potent or very potent) using the British National Formulary (Joint Formulary
Committee). Where trials allowed for any potency of topical corticosteroid to be used as an
intervention, these were categorised in a separate group called “any topical corticosteroid”.
Interventions involving combined therapies were grouped. For example, all interventions of
topical corticosteroids plus an antimicrobial were grouped together. Where topical
corticosteroids were combined with another therapy, the potency was ignored for the purpose
of categorisation. Emollients and vehicles were grouped together as a topical intervention
without the active principle. Further details of all the intervention categories are given in
Supplementary Material 2.
Trial networks
A network of all comparisons between treatments from the RCTs identified in our search was
developed. Two network plots were produced whereby the nodes represented the
interventions and the lines linking the nodes represented a comparison between the two
interventions being linked. In the first plot, the size of the node was proportional to the
number of trials involving that intervention and the thickness of the line was proportional to
the number of trials comparing two interventions. In the second plot, the size of the node was
proportional to the total number of patients who received that intervention across all trials.
Similarly, the thickness of the line was proportional to the number of patients involved in
trials comparing the two interventions.
Trials involving more than two treatment arms of different therapeutic classes were allowed
to contribute to the network more than once. For example, a three arm trial comparing
pimecrolimus, tacrolimus and vehicle contributed to the lines linking pimecrolimus and
tacrolimus; pimecrolimus and vehicle; and tacrolimus and vehicle.
Co-occurrence
In order to determine whether some head-to-head comparisons of specific interventions were
avoided or preferred the degree of co-occurrence was assessed using the C-score statistic
(Stone and Roberts, 1990). The C-score is estimated by first examining each particular pair of
treatments within the network. The number of times each of the two treatments appear in the
network is noted along with the number of times the two treatments are directly compared.
This gives an idea of how many times the two treatments could have been compared, given
their relative frequencies. The C-score statistic is obtained by averaging over all possible
pairs of treatments in the network. Therefore, the C-score reflects the tendency for treatment
comparisons not to occur in the network. A larger C-score corresponds to a larger degree of
co-occurrence in the network, meaning that there is more likely to be a selective pattern in the
choices of treatment comparisons within the network (Salanti et al., 2008).
In order to assess the statistical significance of the C-score statistic a permutations procedure
is applied which asks the underlying question: Given the number of studies in our network
each comparing two treatments, and given the number of times each of those treatments
appear in the network, what are the chances of observing the estimated C-score statistic? This
procedure produces a 95% confidence interval and a p-value for the estimated C-score under
the null hypothesis that there is no selective pattern in the network. A significant p-value
(<0.05) indicates that the estimated C-score is unlikely to be due to chance and that there are
selective patterns in the choices of treatment comparisons in the network.
Analyses were carried out using R software version 3.1.0 with the package EcoSimR and the
NodeXL add-in with Excel.
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Characteristics of RCTs N = 174 RCTs
Trials involving:
Pimecrolimus 39 (22.4%)
Tacrolimus 0.03% 20 (11.5%)
Tacrolimus 0.01% 22 (12.6%)
Tacrolimus 0.3% 2 (1.1%)
Tacrolimus (strength not stated or multiple strengths used) 5 (2.9%)
Mild topical corticosteroids 61 (35.1%)
Moderate topical corticosteroids 26 (14.9%)
Potent topical corticosteroids 65 (37.4%)
Very potent topical corticosteroids 2 (1.1%)
Sample size: median (inter-quartile range) 71 (30, 200.5)
Trials involving:
Children <18 years old only 67 (38.5%)
         Adults ≥18 years old only 55 (31.6%) 
Children and adults 47 (27.0%)
Not stated 5 (2.9%)
Design of the trial:
Parallel 71 (40.8%)
Within person / split body 44 (25.3%)
Crossover 5 (2.9%)
Unclear / not stated 54 (31.0%)
Study funding:
Industry funded (either fully or in part) 91 (52.3%)
Non-industry funded (e.g. solely charity or Government
funded)
11 (6.3%)
Not stated 72 (41.4%)
Table 1: Characteristics of atopic eczema randomised controlled trials (RCTs) involving
pimecrolimus, tacrolimus or topical corticosteroids.
Number of trials
comparing
pimecrolimus with:
N = 39
RCTs¥
Number
industry funded
Number non-
commercially
funded
Number
unknown
funder
Mild TCS 1 (2.6%) 0 (0%) 0 (0%) 1 (100%)
Moderate TCS 3 (7.7%) 2 (66.7%) 0 (0%) 1 (33.3%)
Potent TCS 4 (10.3%) 2 (66.7%) 1 (33.3%) 1 (33.3%)
Tacrolimus 0.03% 2 (5.1%) 2 (100%) 0 (0%) 0 (0%)
Tacrolimus 0.1% 3 (7.7%) 3 (100%) 0 (0%) 0 (0%)
Any tacrolimus 1 (2.6%) 0 (0%) 0 (0%) 1 (100%)
Vehicle/emollient 25 (64.0%) 21 (84.0%) 0 (0%) 4 (16.0%)
Number of trials
comparing
tacrolimus 0.03%
with:
N = 20
RCTs*¥
Number
industry funded
Number non-
commercially
funded
Number
unknown
funder
Mild TCS 3 (15%) 3 (100%) 0 (0%) 0 (0%)
Potent TCS 3 (15%) 2 (66.7%) 0 (0%) 1 (33.3%)
Any TCS 1 (5.9%) 0 (0%) 0 (0%) 1 (100%)
Vehicle/emollient 11 (55%) 8 (72.7%) 0 (0%) 3 (27.3%)
Number of trials
comparing
tacrolimus 0.1%
with:
N = 22
RCTs*¥
Number
industry funded
Number non-
commercially
funded
Number
unknown
funder
Mild TCS 6 (27.3%) 5 (83.3%) 0 (0%) 1 (16.7%)
Moderate TCS 2 (10%) 1 (50%) 1 (50%) 0 (0%)
Potent TCS 3 (15%) 3 (100%) 0 (0%) 0 (0%)
Tacrolimus & Potent
TCS
1 (5%) 1 (100%) 0 (0%) 0 (0%)
Vehicle/emollient 7 (31.8%) 6 (85.7%) 0 (0%) 1 (14.3%)
Number of trials
comparing
tacrolimus 0.3%
with:
N = 2
RCTs*¥
Number
industry funded
Number non-
commercially
funded
Number
unknown
funder
Vehicle/emollient 2 (100%) 2 (100%) 0 (0%) 0 (0%)
Number of trials
comparing mild
TCS with:
N = 62
RCTs¥
Number
industry funded
Number non-
commercially
funded
Number
unknown
funder
Moderate TCS 9 (14.5%) 2 (22.2%) 0 (0%) 7 (77.8%)
Potent TCS 17 (27.4%) 6 (35.3%) 1 (5.9%) 10 (58.8%)
TCS plus another
intervention
6 (9.7%) 2 (33.3%) 1 (16.6%) 3 (50%)
Vehicle/emollient 15 (24.2%) 6 (40.0%) 3 (20%) 6 (40.0%)
Other type of
intervention
7 (11.3%) 4 (57.1%) 0 (0%) 3 (42.9%)
Number of trials
comparing
moderate TCS with:
N = 26
RCTs¥
Number
industry funded
Number non-
commercially
funded
Number
unknown
funder
Potent TCS 6 (23.1%) 0 (0%) 0 (0%) 6 (100%)
Vehicle/emollient 5 (19.2%) 2 (40%) 0 (0%) 3 (60%)
Other type of
intervention
1 (3.8%) 0 (0%) 0 (0%) 1 (100%)
Number of trials
comparing potent
TCS with:
N = 62
RCTs¥
Number
industry funded
Number non-
commercially
funded
Number
unknown
funder
Any tacrolimus 1 (1.6%) 0 (0%) 0 (0%) 1 (100%)
Very potent TCS 1 (1.6%) 0 (0%) 0 (0%) 1 (100%)
TCS plus another
intervention
3 (4.8%) 0 (0%) 0 (0%) 3 (100%)
Vehicle/emollient 21 (33.9%) 10 (47.6%) 3 (14.3%) 8 (38.1%)
Other type of
intervention
3 (4.8%) 1 (33.3%) 1 (33.3%) 1 (33.3%)
Table 2: Number of trials comparing topical corticosteroids pimecrolimus, tacrolimus and
vehicle/emollient.
*Some trials involved more than one strength of tacrolimus. There were 41 trials in total that
involved tacrolimus.
¥Not all of the columns for each intervention will add up to the total N shown. This is because
comparisons are not repeated down the table. For example, the numbers for pimecrolimus
compared with mild TCS are given in the pimecrolimus section and therefore are not repeated
under the mild TCS section of the table.
Figure 1: Network of RCTs for atopic eczema involving pimecrolimus, tacrolimus or topical
corticosteroids. Nodes represent the interventions – two nodes are linked together with a line
if at least one trial compared the two interventions. The size of the node is proportional to the
number of trials involving that intervention. Similarly, the thickness of the line is
proportional to the number of trials comparing the two interventions. The lines are labelled
with the number of comparisons if the number was greater than 1. “Any TCS” represents
interventions where participants were allowed to apply any potency of topical corticosteroid.
“Any tacrolimus” represents interventions where participants were allowed to apply any
strength of tacrolimus or where the study did not state the strength of tacrolimus used.

Supplementary Material 1 - GREAT Database Search 
strategy 
The MEDLINE and EMBASE databases, the Cochrane Library and the Skin Group Specialised 
Register were searched from inception, as follows: 
MEDLINE (2000 onwards) 
1. randomized controlled trial.pt. 
2. controlled clinical trial.pt. 
3. randomized.ab. 
4. placebo.ab. 
5. drug therapy.fs. 
6. randomly.ab. 
7. trial.ab. 
8. groups.ab. 
9. 6 or 3 or 7 or 2 or 8 or 1 or 4 or 5 
10. (animals not (humans and animals)).sh. 
11. 9 not 10 
12. exp Dermatitis, Atopic/ 
13. atopic dermatitis.mp. 
14. atopic eczema.mp. 
15. exp NEURODERMATITIS/ 
16. neurodermatits.mp. 
17. infantile eczema.mp. 
18. childhood eczema.mp. 
19. Besniers' Prurigo.mp. 
20. exp Eczema/ or eczema.mp. 
21. 17 or 12 or 20 or 15 or 14 or 18 or 13 or 16 or 19 
22. 11 and 21 
  
EMBASE (2000 onwards) 
1. random$.mp. 
2. factorial$.mp. 
3. (crossover$ or cross-over$).mp. 
4. placebo$.mp. or PLACEBO/ 
5. (doubl$ adj blind$).mp. 
6. (singl$ adj blind$).mp. 
7. (assign$ or allocat$).mp. 
8. volunteer$.mp. or VOLUNTEER/ 
9. Crossover Procedure/ 
10. Double Blind Procedure/ 
11. Randomized Controlled Trial/ 
12. Single Blind Procedure/ 
13. 1 or 2 or 3 or 4 or 5 or 6 or 7 or 8 or 9 or 10 or 11 or 12 
14. exp Dermatitis, Atopic/ 
15. atopic dermatitis.mp. 
16. atopic eczema.mp. 
17. exp NEURODERMATITIS/ 
18. neurodermatitis.mp. 
19. infantile eczema.mp. 
20. childhood eczema.mp. 
21. (besnier$ and prurigo).mp. 
22. eczema.mp. or exp Eczema/ 
23. 21 or 17 or 20 or 15 or 14 or 22 or 18 or 16 or 19 
24. 23 and 13 
From 2000 onwards, the CINHAL, AMED and LILACS databases have also been searched using the 
same terms for eczema and appropriate terms to identify RCTS. 
  
  
SUPPLEMENTARY MATERIAL  2 – BREAKDOWN OF INTERVENTION 
CATEGORIES 
 
Category Types of Interventions 
Pimecrolimus  All doses of pimecrolimus. 
*Interventions of pimecrolimus + another therapy are included as a 
separate category. 
Tacrolimus 0.03%  All doses of tacrolimus 0.03% 
Tacrolimus 0.1%  All doses of tacrolimus 0.1% 
Tacrolimus 0.3%  All doses of tacrolimus 0.3% 
Any tacrolimus  Trials where patients were allowed to receive any strength of 
tacrolimus or where the strength was not stated. 
*Interventions of tacrolimus + another therapy are included as a separate 
category regardless of the strength of tacrolimus used. 
Mild potency topical 
corticosteroids 
 Hydrocortisone 0.5, 1 and 2.5% cream/ointment 
 Flumethasone pivalate (Locorten) 0.03% 
 Prednicarbate 
Moderate potency 
topical 
corticosteroids 
 Clobetasone butyrate 0.05% (Eumovate®) cream/ointment 
 Betamethasone 0.025% (Betnovate RD®) cream/ointment 
 Fludroxycortide tape (Haelan®) 
 Desonide 0.05% 
 Fluorocortolone 0.25% 
 Halometasone 0.05% 
 Alclometasone dipropionate 0.05% (Modrasone) 
 Fluprednidene acetate  
 Fludroxycortide (flurandrenolone) 0.0125% Haelan® 
Potent topical 
corticosteroids 
 Betamethasone 0.1% cream / ointment / lotion (Betnovate®) 
 Betamethasone 0.05% with salicylic acid 3% (Diprosalic®) 
ointment 
 Mometasone furoate 0.1% (Elocon®) cream/ointment 
 Fluticasone propionate cream 0.05% or ointment 0.005% 
(Cutivate) 
 Fluocinonide 0.05% cream/ointment 
 Triamcinolone acetonide 0.1% 
 Desoximethasone 
 Methylprednisolone aceponate 0.1% 
 Fucicort (Fusidic acid and betamethasone 17-valerate) 
 Diflorasone diacetate 0.05% 
 Halicinonide 
 Topical budesonide 0.025% 
 Beclomethasone  
Any topical 
corticosteroids 
 Trials where patients were allowed to receive any potency of 
TCS. 
*Potency was grouped for all trials where the intervention was TCS + 
another therapy 
Very potent topical 
corticosteroids 
 Clobetasol propionate 0.05% (Dermovate®) cream/ointment 
 Diflucortolone 0.3% (Nerisone forte®) oily cream/ointment 
Antimicrobial  Mupirocin ointment (Bactroban) 
 Tetracycline (TT) ointment 
 Miconazole cream 
 Miltefosine solution (Miltex ®) 
 Sertaconazole cream (Dermoﬁx, Ferrer Co., Spain) 
Occlusion  Coverflex® tubular bandage 
 Wet wraps (tubifast bandages) 
Complimentary 
therapy 
 
 Kamillosan ® cream (camomile) 
 Herba Saxifragae cream 
 Thermal water 
 Hamamelis 
Laser  UVA/UVB monotherapy 
 XeCl gas 308nm excimer laser (Talos ® - 10 or 20mm spot size, 
200mW per cm, 60ns, 200Hz) 
Antipruritic  Pramoxine hydrochloride lotion 
 Oral cetirizine 
 Terfenadine 
 Topical doxepin 
Vehicle / Emollient  Any trial including an intervention referred to as a “vehicle” 
 MAS063DP emollient cream 
 Emollient containing Sunflower Oleodistillate (Stelatopia ®) 
 Ceramide-hyaluronic acid based emollient foam 
 Moisturizer containing licochalcone A 
 Floderm Topical Cream - Drex Pharma 
 Oil-in-water Emolient containing licochalcone A 
 Moisturizer containing spent grain wax, Butyrospermum parkii 
extract, Argania spinosa kernel oil 
 Emollient (Advabase ®) 
 Eletone containing high lipid content, utilises specialized 
Hydrolipid technology 
 Vaseline 
 WWT with emollient (petroleum 20% in cetomacrogol cream) 
 Moisturiser 
Other interventions  Methyl-lipoxin 
 Montelukast 
 Coal tar 
 Cerimide-dominant barrier repair formulation 
 
 
 
  
 SUPPLEMENTARY 
MATERIAL  3 
 
Network of RCTs for atopic 
eczema involving 
pimecrolimus, tacrolimus or 
topical corticosteroids 
weighted by the number of 
patients in the trial. 
 
Nodes represent the 
interventions – two nodes are 
linked together with a line if at 
least one trial compared the 
two interventions. The size of 
the node is proportional to the 
number of patients receiving 
that intervention across all 174 
RCTs. Similarly, the thickness 
of the line is proportional to 
the number of patients 
involved in RCTs that 
compare the two interventions. 
The lines are labelled with the 
total sample size if the sample 
size was greater or equal to 
500. “Any TCS” represents 
interventions where 
participants were allowed to 
apply any potency of topical 
corticosteroid. “Any 
tacrolimus” represents 
interventions where 
participants were allowed to 
apply any strength of 
tacrolimus or where the study 
did not state the strength of 
tacrolimus used. 
 
